「Targeting Activated HER2 in Solid Tumor」癌研有明病院共催

Focus Symposium (癌研有明病院共催)
Theme: Targeting Activated HER2 in Solid Tumor
Speaker: Dr.Mark Sliwkowski(Genentech, Inc. )
symposium_img Abstract:
Herceptin, in combination with chemotherapy, is regarded as the standard of care in the treatment of HER2-positive breast cancer and promising data are also emerging in gastric cancer. Unfortunately, some patients with metastatic breast cancer are observed to progress on HER2-directed tharpies. To address this unmet clinical need, we are developing alternative monoclonal antibody therapies.
公益財団法人東京生化学研究会 CHAAO事業